Literature DB >> 10847559

L-glutamate, L-arginine and L-citrulline levels in cerebrospinal fluid of Parkinson's disease, multiple system atrophy, and Alzheimer's disease patients.

M A Kuiper1, T Teerlink, J J Visser, P L Bergmans, P Scheltens, E C Wolters.   

Abstract

Alterations in neuronal nitric oxide (NO) production may play a role in the pathophysiology of Parkinson's disease (PD) Alzheimer's disease (AD), and multiple system atrophy (MSA). The biosynthesis of NO is dependent on the availability of L-arginine, the substrate for NO-synthase (NOS), and on L-glutamate, which stimulates NO synthesis via the NMDA receptor. In this process L-citrulline is formed. We measured the levels of these amino acids in cerebrospinal fluid (CSF) of 108 PD patients, 12 AD patients, 15 MSA patients and 21 healthy subjects. A slight but statistically significant elevation of CSF L-citrulline was found in MSA patients, while CSF L-glutamate was found to be significantly decreased in AD patients. We found no significant changes in L-arginine levels. Although the relation between the CSF levels of these amino acids and neuronal NO production is still unclear, our findings suggest that AD is associated with a decrease in NO synthesis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10847559     DOI: 10.1007/s007020050016

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  22 in total

Review 1.  Biomarkers for cognitive impairment in Parkinson disease.

Authors:  Min Shi; Bertrand R Huber; Jing Zhang
Journal:  Brain Pathol       Date:  2010-05       Impact factor: 6.508

Review 2.  The role of inflammatory processes in Alzheimer's disease.

Authors:  G Joseph Broussard; Jennifer Mytar; Rung-chi Li; Gloria J Klapstein
Journal:  Inflammopharmacology       Date:  2012-04-26       Impact factor: 4.473

3.  L-arginine and Alzheimer's disease.

Authors:  Jing Yi; Laura L Horky; Avi L Friedlich; Ying Shi; Jack T Rogers; Xudong Huang
Journal:  Int J Clin Exp Pathol       Date:  2008-10-02

Review 4.  Therapeutic potential of targeting glutamate receptors in Parkinson's disease.

Authors:  Clare Finlay; Susan Duty
Journal:  J Neural Transm (Vienna)       Date:  2014-02-21       Impact factor: 3.575

5.  Low striatal glutamate levels underlie cognitive decline in the elderly: evidence from in vivo molecular spectroscopy.

Authors:  Natalie M Zahr; Dirk Mayer; Adolf Pfefferbaum; Edith V Sullivan
Journal:  Cereb Cortex       Date:  2008-01-29       Impact factor: 5.357

Review 6.  Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease.

Authors:  Susan Duty
Journal:  CNS Drugs       Date:  2012-12       Impact factor: 5.749

7.  Translational control of inducible nitric oxide synthase expression by arginine can explain the arginine paradox.

Authors:  Junghee Lee; Hoon Ryu; Robert J Ferrante; Sidney M Morris; Rajiv R Ratan
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-24       Impact factor: 11.205

8.  Impairment of Nrf2- and Nitrergic-Mediated Gastrointestinal Motility in an MPTP Mouse Model of Parkinson's Disease.

Authors:  C Sampath; R Kalpana; T Ansah; C Charlton; A Hale; K M Channon; S Srinivasan; P R Gangula
Journal:  Dig Dis Sci       Date:  2019-06-11       Impact factor: 3.199

9.  Changes in amino acids and nitric oxide concentration in cerebrospinal fluid during labor pain.

Authors:  Rama Sethuraman; Tat-Leang Lee; Jen-Wun Chui; Shinro Tachibana
Journal:  Neurochem Res       Date:  2006-08-29       Impact factor: 4.414

Review 10.  Neurochemical approaches in the laboratory diagnosis of Parkinson and Parkinson dementia syndromes: a review.

Authors:  Sarah Jesse; Petra Steinacker; Stefan Lehnert; Frank Gillardon; Bastian Hengerer; Markus Otto
Journal:  CNS Neurosci Ther       Date:  2009-03-09       Impact factor: 5.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.